Cancer/Tumor Profiling Market - Global Forecast to 2021

Dublin, April 09, 2018 -- The "Cancer/Tumor Profiling Market by Application (Diagnostic, Personalized Medicine, Research), Technique (Genomics, Proteomics, Metabolomics, Epigenetics),Technology (Next-generation Sequencing, In-situ Hybridization, Microarray)- Forecast to 2021" report has been added to ResearchAndMarkets.com's offering.

Global Cancer/Tumor Profiling Market is Projected to Reach USD 8.74 Billion in 2022 from USD 5.26 Billion in 2017 at CAGR of 10.7%.

The cancer/tumor profiling market is dominated by established players such as Illumina (US), QIAGEN (Netherlands), NeoGenomics Laboratories (US), HTG Molecular Diagnostic (US), and Genomic Health (US).

The cancer/tumor profiling market is primarily driven by the increasing number of cancer cases, growing utility of biomarkers in tumor profiling, and availability of funding for cancer research. In addition, the introduction and adoption of point-of-care diagnostic tests and development of personalized medicine are expected to offer growth opportunities for manufacturers of cancer/tumor profiling solutions. However, high capital investments and low benefit ratio of biomarkers are restraining the growth of this market.

On the basis of technology, the global cancer/tumor profiling market is broadly divided into immunoassays, hybridization, NGS, mass spectrometry, and other technologies. In 2017, the immunoassays segment is expected to account for the largest share of the cancer/tumor profiling technologies market. The high sensitivity and cost-effectiveness of these techniques as well as technological advancements in these immunoassays tests are factors that are expected to propel the growth of this market in the coming years.

Furthermore, the hybridization technology is again divided on the basis of type which includes PCR, in-situ hybridization, and microarrays. The PCR segment is expected to account for the largest market share of hybridization technology in 2017. PCR is one of the most widely used technologies in the diagnostics market. This is primarily due to its ease of use, cost-effectiveness, quick turnaround time (4 to 6 hours), and easy availability of kits and reagents.

Based on application, the cancer/tumor profiling market is categorized into clinical application, and research application. In 2017, the clinical application segment is expected to account for the largest share of the cancer/tumor profiling market. Technological advancements and the need for early diagnosis are further aiding market growth in this segment.

Among the four regions, North America is expected to account for the largest share of the cancer/tumor profiling market in 2017, followed by Europe, APAC, and the RoW. The large share of the North American market is mainly attributed to the increasing government support for discovery and development of biomarkers, increasing demand for personalized medicine, adoption of advanced omics technologies for biomarker discovery, and rising use of biomarkers in drug discovery and development by pharmaceutical companies in that region.

Key Topics Covered:

1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.2.1 Markets Covered
1.3 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology
2.1 Market Size Estimation
2.2 Market Breakdown And Data Triangulation
2.3 Macroeconomic Factor Analysis
2.3.1 Introduction
2.3.2 Demand-Side Analysis
2.3.2.1 Healthcare Expenditure Pattern
2.3.3 Supply-Side Analysis
2.3.3.1 Number of New Product Launches

3 Executive Summary

4 Premium Insights
4.1 Cancer/Tumor Profiling: Market Overview
4.2 Geographic Analysis: Cancer/Tumor Profiling Market, By Technology (2017)
4.3 Cancer/Tumor Profiling Market, By Application
4.4 Cancer/Tumor Profiling Market, By Hybridization Technology
4.5 Geographical Snapshot of the Cancer/Tumor Profiling Market

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Increasing Number of New Cancer Cases
5.2.1.2 Increasing Utility of Biomarkers in Tumor Profiling
5.2.1.3 Availability of Funding for Cancer Research
5.2.2 Restraints
5.2.2.1 High Capital Investments And Low Benefit Ratio for Biomarkers
5.2.2.2 Lack of Skilled Professionals And Infrastructure
5.2.3 Opportunities
5.2.3.1 Point-Of-Care Diagnostic Tests
5.2.3.2 Increasing Demand for Personalized Medicine
5.2.4 Challenge
5.2.4.1 Unclear Regulatory And Reimbursement Scenario

6 Cancer/Tumor Profiling Market, By Technology
6.1 Introduction
6.2 Immunoassays
6.3 Hybridization
6.3.1 Pcr
6.3.2 in Situ Hybridization (Ish)
6.3.3 Dna/Rna Microarray
6.4 Next Generation Sequencing
6.5 Mass Spectrometry
6.6 Other Technologies

7 Cancer/Tumor Profiling Market, By Cancer Type
7.1 Introduction
7.2 Breast Cancer
7.3 Lung Cancer
7.4 Colorectal Cancer
7.5 Prostate Cancer
7.6 Melanoma Cancer
7.7 Others Cancer

8 Cancer/Tumor Profiling Market, By Application
8.1 Introduction
8.2 Clinical Application
8.3 Research Application

9 Cancer/Tumor Profiling Market, By Region
9.1 Introduction
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.4 Asia-Pacific
9.5 Rest of the World (Row)

10 Competitive Landscape
10.1 Overview
10.2 Battle for Market Share: Product Launch Was the Key Growth Strategy Adopted By Market Players Between 2013 And 2016
10.3 Product Launches
10.4 Agreements, Collaborations, And Partnerships
10.5 Acquisitions
10.6 Others Strategies

11 Company Profiles

• Caris Life Sciences
• Genomic Health Inc.
• Helomics Corporation
• Htg Molecular Diagnostics, Inc.
• Illumina, Inc.
• Nanostring Technologies, Inc.
• Neogenomics Laboratories, Inc.
• Oxford Gene Technology
• Qiagen N.V.
• Ribomed Biotechnologies, Inc.

For more information about this report visit https://www.researchandmarkets.com/research/pmrkd9/cancertumor?w=12

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Diagnostics